| 标题 |
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies |
| 网址 | |
| DOI |
10.1182/blood-2023-179872
doi
|
| 其它 |
期刊:Blood 作者:Alexey V. Danilov; M. Tees; K. Patel; W. Wierda; M. Patel; et al 出版日期:2023-11-28 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)